TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.3204
+0.0025 (0.79%)
At close: Sep 11, 2026, 4:00 PM EDT
0.3202
-0.0002 (-0.06%)
After-hours: Sep 11, 2026, 6:27 PM EDT
TScan Therapeutics Revenue
TScan Therapeutics had revenue of $1.05M in the quarter ending June 30, 2026, a decrease of -65.83%. This brings the company's revenue in the last twelve months to $7.11M, up 2.15% year-over-year. In the year 2025, TScan Therapeutics had annual revenue of $10.33M with 266.65% growth.
Revenue (ttm)
$7.11M
Revenue Growth
+2.15%
P/S Ratio
3.05
Revenue / Employee
$51,529
Employees
138
Market Cap
21.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.33M | 7.51M | 266.65% |
| Dec 31, 2024 | 2.82M | -18.23M | -86.62% |
| Dec 31, 2023 | 21.05M | 7.51M | 55.52% |
| Dec 31, 2022 | 13.54M | 3.39M | 33.47% |
| Dec 31, 2021 | 10.14M | 9.06M | 834.65% |
| Dec 31, 2020 | 1.09M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
TCRX News
- 4 days ago - TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 9 days ago - TScan downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 10 days ago - Needham downgrades TScan Therapeutics as company reprioritizes - TheFly
- 10 days ago - TScan Therapeutics downgraded to Hold from Buy at Needham - TheFly
- 10 days ago - TScan Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 10 days ago - TScan Therapeutics Transcript: Study update - Transcripts
- 10 days ago - TScan Therapeutics Press release: Study update - Filings
- 10 days ago - TScan Therapeutics Slides: Study update - Filings